- Home
- CPRX vs NAMS Comparison
CPRX vs NAMS Comparison
Compare CPRX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | NAMS |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | CPRX | NAMS |
|---|---|---|
| Price | $23.16 | $35.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $32.60 | ★ $45.80 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.94 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $578,196,000.00 | $35,243,000.00 |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $7.21 | N/A |
| P/E Ratio | $13.35 | ★ N/A |
| Revenue Growth | ★ 25.56 | 4.91 |
| 52 Week Low | $19.05 | $14.06 |
| 52 Week High | $26.58 | $42.00 |
Technical Indicators
Market Signals| Indicator | CPRX | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 44.99 |
| Support Level | $22.20 | $34.59 |
| Resistance Level | $23.84 | $36.14 |
| Average True Range (ATR) | 0.59 | 1.73 |
| MACD | -0.10 | -0.57 |
| Stochastic Oscillator | 57.39 | 16.18 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.